FindTrial
Sign In

A single center prospective study comparing the effects of induction therapy in Chinese donation after cardiac death (DCD) patients between rabbit anti-human thymocyte immunoglobulin (Thymoglobulin) and basiliximab ( Simulect)

A single center prospective study comparing the effects of induction therapy in Chinese donation after cardiac death (DCD) patients between rabbit anti-human thymocyte immunoglobulin (Thymoglobulin) and basiliximab ( Simulect)

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017266
Enrollment
Unknown
Registered
2018-07-20
Start date
2018-07-21
Completion date
Unknown
Last updated
2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Interventions

1:rATG standard dose (5.0-6.0 mg/kg)
2:rATG standard dose (4.0-5.0 mg/kg)
3:Basiliximab standard dose

Sponsors

General Hospital of Chinese People's Armed Police Forces
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Patients received DCD (including donation after brain death followed by circulatory death, DBCD) kidney transplantation; 2) Patient aged above 18 years old; 3) Patients who received rATG or Basiliximab as induction immunosuppresive therapy.

Exclusion criteria

Exclusion criteria: 1) Patients who transplanted multiple organs 2) Previously transplanted patients

Design outcomes

Primary

MeasureTime frame
acute rejection rate;—

Secondary

MeasureTime frame
delayed graft function;graft/patient survival rate;infection rate;—

Countries

China

Contacts

Public ContactJianli Wang

General Hospital of Chinese People's Armed Police Forces

jianlidoc1@163.com+86 13911723417

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026